Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | Yaron Naymark1 Main Capital | DIAMEDICA THERAPEUTICS INC $DMAC• NASDAQ | -- | Long DMAC (DIAMEDICA THERAPEUTICS INC) The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic) form of the natural | BULL | View Pitch → |
| Aug 1, 2026 | Fund Letter | Yaron Naymark1 Main Capital | DIAMEDICA THERAPEUTICS INC $DMAC• NASDAQ | -- | 1 Main Capital - DMAC The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic)... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.